When ASMs are used for LGS treatment, the use of a sodium-channel blocker is recommended for LGS with polymorphism in sodium or potassium channels attributed to variations in SCN2A, SCN8A, and KCNQ2 (23). This evidence concerns the gene KCNA3 and Lennox-Gastaut syndrome.